An aetiological approach has identified monogenic patients with diabetes due to TCF1 mutations who are particularly sensitive to the hypoglycaemic effects of sulphonylureas , and KCNJ11 or ABCC8 mutations in which sulphonylureas can be used in place of insulin treatment .